Preparation and application of recombinant human fibronectin

Through genetic engineering technology, the human fibronectin sequence and fermented bacterial species were optimized, and the problems of low yield, low purity and poor stability of fibronectin in the prior art were solved, and recombinant fibers with high yield, high purity, low concentration and high activity were obtained. Conjunctin, suitable for medical and cosmetics.

CN119060167AActive Publication Date: 2024-12-03HANGZHOU SANSHENG MEIJIAN BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202411354330.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-31
Filing Date
2024-09-27
Publication Date
2024-12-03
Estimated Expiration
2044-09-27

AI Technical Summary

Technical Problem

The existing fibronectin source sequence is not completely human, with immunogenic problems, low production process yield, cumbersome purification process, low purity and poor stability, resulting in difficulty in large-scale production, large molecular weight, strong hydrophilicity, and difficult to penetrate Exercise functions through the skin.

Method used

Through genetic engineering technology, the amino acid sequence of human fibronectin is optimized, the fusion protein is constructed with tag proteins, and the expression of fermented bacteria is optimized. Nickel column affinity chromatography and enzyme cleavage are used to obtain high yield, high purity, low concentration and high activity recombinant human fibronectin.

Benefits of technology

It realizes efficient cell proliferation, adhesion and differentiation functions, improves product application prospects and stability, reduces production costs, and is suitable for medical and cosmetics fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060167A_ABST
    Figure CN119060167A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of recombinant human fibronectin, and belongs to the technical field of genetic engineering. According to the prepared recombinant human fibronectin, core fragments of the fibronectin are reasonably combined by adjusting the composition of a sequence, unnecessary or some structural domains which have great influence on the structure are removed, and the recombinant human fibronectin is obtained through reasonable optimization. The recombinant human fibronectin with relatively high purity and relatively good yield is obtained, and the recombinant human fibronectin still keeps efficient biological activity in the aspects of cell proliferation, adhesion and differentiation, and has a relatively good application prospect in the aspects of cosmetics, medical instruments and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the preparation and application of recombinant human fibronectin, and belongs to the technical field of genetic engineering. Background Art

[0002] Fibronectin (FN) is a high molecular weight glycoprotein, containing 4.5%-9.5% sugar. It is a multifunctional glycoprotein that is abundant in plasma and widely distributed in the extracellular matrix. Its main function is to mediate cell adhesion. Fibronectin (FN) is a large glycoprotein with a molecular weight of about 440,000 Daltons. It is a dimer formed by two subunits with a molecular mass of 220,000 Daltons connected by disulfide bonds. The entire molecule is composed of two similar A chains and B chains, in a V shape. There are multiple binding domains on each FN subunit that are closely related to function: 2 heparin binding domains; 3 fibrin binding domains; 1 collagen binding domain. The collagen binding domain on FN binds to collagen in the cell matrix, thereby adsorbing cells to the extracellular matrix; 1~2 eukaryotic cell binding domains are on Fn III 10, and the second is located on Fn III 9. Fibronectin recognizes and binds to integrin heterodimers through the arginine-glycine-aspartic acid sequence (Arg-Gly-Asp, RGD) on fibronectin Fn III 10 and Fn III 9, thereby affecting cell adhesion and migration. Purified fibronectin can enhance cell-to-cell adhesion and cell-to-matrix adhesion. Cell adhesion and migration are the result of specific recognition, binding and interaction between cells and extracellular matrix. The interaction between extracellular matrix protein molecules and the corresponding receptor integrins on the cell membrane is an important mechanism that determines cell adhesion and migration. The interaction between the ligand molecule fibronectin and the corresponding integrin is the central link in the regulation of cell adhesion and migration. FN can connect cells to the extracellular matrix.

[0003] Fibronectin has multiple adhesion functions, such as cell-cell adhesion, and is also important in wound healing. Soluble fibronectin deposited on damaged collagen and fibrin enhances platelet adhesion, phagocyte and fibroblast migration, and cell proliferation. In addition to adhesion, fibronectin can also regulate cell shape and cytoskeleton organization through cell signal transduction pathways and promote cell spreading. During embryogenesis, fibronectin is essential for the migration and differentiation of many types of cells. Fibronectin is also important in wound repair. During blood clot formation, fibronectin promotes platelet adhesion to damaged blood vessels. Therefore, fibronectin has broad application prospects in the fields of medicine, beauty, and skin care.

[0004] Although animal tissues and blood contain fibronectin, the content is extremely limited, and the protein extracted from animals is a full-length protein with poor skin permeability, resulting in low yield, high cost, low product purity, and low skin permeability of tissue-derived fibronectin. Naturally extracted fibronectin has a large molecular weight and is not uniform. The extracted protein pure product has a limited content and is difficult to form a large-scale production scale. Products extracted from animals have limitations such as low product purity, the risk of carrying viruses, the risk of immunogenicity, and high cost. Therefore, it is necessary to express and prepare high-purity humanized fibronectin in prokaryotic or eukaryotic microorganisms through genetic engineering technology.

[0005] The existing fibronectin source sequences are not completely human, and there may be problems with immunogenicity in application scenarios, which limits its application scenarios. In terms of production technology, there are problems such as low yield in the fermentation process and easy plasmid loss in the fermentation strain. There are problems such as cumbersome purification process, low purity, and low purification yield, which are not conducive to large-scale production and purification. At present, the development of recombinant human fibronectin has been carried out in succession, but there are a series of problems, such as low yield, which cannot form a large-scale production; low purity, and certain safety risks in large-scale production; low activity, and high cost of large-scale production; poor stability, high cost of large-scale production, and it is not conducive to product use, and the application scenario is simple; in addition, the molecular weight of the recombinant fibronectin currently produced is relatively large, and its hydrophilicity is strong, which is not easy to penetrate the skin and difficult to exert its function. Summary of the invention

[0006] In view of the deficiencies in the above-mentioned prior art, the present invention provides a preparation and application of recombinant fibronectin, aiming to solve the problem that some fibronectin source sequences are not completely human, and there may be problems of immunogenicity in application scenarios, and its application scenarios are limited; in terms of molecular weight, there are problems such as difficulty in penetration; in terms of production process, there are problems such as low yield in fermentation process and easy plasmid loss in fermentation strains; there are problems such as complicated purification process, low purity, low purification yield, low stability, etc., which are not conducive to large-scale production and purification and other technical problems.

[0007] The first technical solution provided by the present invention is a recombinant human fibronectin, the amino acid sequence of which is shown in SEQ ID NO.1.

[0008] The second technical solution provided by the present invention is a gene encoding the protein described in the first technical solution.

[0009] In certain embodiments, the nucleotide sequence of the gene is shown in any one of SEQ ID NOs. 2 to 4.

[0010] The third technical solution provided by the present invention is a recombinant plasmid carrying the gene described in the second technical solution.

[0011] In certain embodiments, pET32a(+) or pET28a(+) is used as the expression vector.

[0012] The fourth technical solution provided by the present invention is a genetically engineered bacterium, which is a host cell expressing the protein described in the first technical solution, or containing the gene described in the second technical solution, or transformed with the plasmid described in the third technical solution.

[0013] In certain embodiments, the host cell comprises a prokaryotic or eukaryotic microorganism.

[0014] In some embodiments, the host cell is based on Escherichia coli as the starting strain, preferably, E. coli BL21(DE3) was used as the expression host.

[0015] The fifth technical solution provided by the present invention is a method for preparing recombinant fibronectin, which comprises culturing the genetically engineered bacteria described in the fourth technical solution, inducing the bacteria to express recombinant fibronectin, disrupting the bacteria, and obtaining a crude recombinant fibronectin product.

[0016] In certain embodiments, the genetically engineered bacteria are inoculated in TB liquid culture medium, cultured at 37°C, 220 rpm for 4-6 hours, 0.1-1 M IPTG is added, induced at 25-37°C, 220 rpm for 6-8 hours, centrifuged to remove the supernatant, ultrasonically disrupted the bacteria, and centrifuged to collect the supernatant to obtain a crude product.

[0017] In certain embodiments, the crude recombinant fibronectin is purified to obtain a pure recombinant fibronectin.

[0018] Furthermore, the purification process comprises the following steps: the crude recombinant fibronectin is separated by nickel column affinity chromatography to obtain a pure recombinant fibronectin product.

[0019] The sixth technical solution provided by the present invention is the use of the protein described in the first technical solution, or the gene described in the second technical solution, or the plasmid described in the third technical solution, or the genetically engineered bacteria described in the fourth technical solution, or the method described in the fifth technical solution in the preparation of a product containing fibronectin.

[0020] The seventh technical solution provided by the present invention is a method for detecting the activity of fibronectin, wherein the method cultured mouse fibroblasts NIH 3T3 in 1640 medium to which a fibronectin sample to be detected was added, and after 60 hours, the medium was replaced with 1640 medium containing 10% CCK8 for 2 hours, and the absorbance was detected at 450 nm; Alternatively, the method is to culture human keratinocytes HaCaT in a DMEM medium supplemented with a fibronectin sample to be detected, replace it with a DMEM medium containing 0.5 mg / mL MTT after 24 hours, culture it for 4 hours, discard the supernatant DMSO, and detect the absorbance at 570 nm.

[0021] Compared with the prior art, the present invention has the following beneficial effects: The human fibronectin sequence selected by the present invention is combined and optimized to obtain the original amino acid sequence, and the original amino acid sequence is optimized by codons so that it can be heterologously expressed in microorganisms. At the same time, some tags are selected as auxiliary proteins of recombinant fibronectin to construct fusion proteins, and the fusion proteins are constructed on protein expression vectors and transformed into microorganisms; and the expression of fermented strains is optimized to obtain microbial strains with high yield of fibronectin; the strains are crushed, column chromatography, enzyme cutting and other methods are used to obtain recombinant human fibronectin; its active protein activity is detected by pharmacopoeia method, and has the characteristics of high activity at low concentration. The present invention obtains recombinant human fibronectin with high purity and good yield, and the recombinantly expressed human fibronectin still retains efficient biological activity in cell proliferation, adhesion and differentiation, and has good application prospects in cosmetics, medical devices and other aspects. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 It is used to predict the structure of proteins under different tags.

[0023] Figure 2 Schematic diagram of the Escherichia coli recombinant plasmid containing recombinant human fibronectin.

[0024] Figure 3 This is the nucleic acid electrophoresis diagram of the recombinant plasmid, where lane 1: pET32a(+)+original recombinant human fibronectin gene fragment; lane 2: 10 kb DNA marker.

[0025] Figure 4 This is the SDS-PAGE image of the Wild type of Escherichia coli genetically engineered strain expressing high copy number of recombinant human fibronectin and the supernatant of the broken cell wall of the high copy number of Escherichia coli genetically engineered strain expressing recombinant human fibronectin (induced for 5 hours).

[0026] Figure 5 This is a comparison of the purity of recombinant human fibronectin from different sources (HPLC). The left picture shows the fibronectin from a commercial company, and the right picture shows the fibronectin of the present invention.

[0027] Figure 6 These are the results of the thermal stability experiment of recombinant human fibronectin.

[0028] Figure 7These are the results of the freeze-thaw stability experiment of recombinant human fibronectin.

[0029] Figure 8 The results are for detecting the proliferation activity of mouse fibroblast NIH 3T3 cells.

[0030] Fig. 9 This is a diagram showing the test results of the method for testing the proliferation activity of human keratinocytes.

[0031] Fig.10 This is the SDS-PAGE diagram of fermentation optimization of recombinant human fibronectin. Lane 1 is the original sequence without codon optimization, lane 2 is the untagged sequence after codon optimization, lane 3 is the conventional fermentation result of TrxA tag; lane 4 is the optimized fermentation result of TrxA tag; lane 5 is the uninduced protein band.

[0032] Fig.11 This is a comparison of the purity of recombinant human fibronectin from different sources (SDS-PAGE). Lane 1 is the fibronectin obtained by other purification methods, lane 2 is the fibronectin shown in the present invention, and lane 3 is the fibronectin method of a commercial company. DETAILED DESCRIPTION

[0033] The preferred embodiments of the present invention are described below. It should be understood that the embodiments are for better explaining the present invention and are not used to limit the present invention.

[0034] Test method: 1. HPLC detection of fibronectin: The present invention refers to the guidelines of 0512 High Performance Liquid Chromatography and 0532 Critical Point Chromatography of the Chinese Pharmacopoeia, and refers to the industry standard YY / T 1805.3-2022 method, and selects a suitable SEC molecular sieve for detection; the mobile phase is 20 mM PBS aqueous solution; the flow rate is 0.5 ml / min.

[0035] 2. Measurement of protein solubility: The present invention uses the first method of Kjeldahl nitrogen determination method in General Rule 0731 of the Chinese Pharmacopoeia to measure the protein solution content, calculate the total amount of protein, freeze-dry the elastin solution using a freeze-drying device, turn the solution into powder, and gradually dissolve the protein powder with a small amount of water until it is completely dissolved. The ratio of the total protein amount of the protein solution to the volume of dissolved solids measured can roughly obtain the solubility of the protein.

[0036] Materials used in the examples: 1. The plasmids and cells involved in the following examples are as follows: strains E coli BL21(DE3) and plasmid pET32a(+) are commercial strains and plasmids.

[0037] 2. NIH 3T3 cells were from Science Compass, and HaCaT cells were from Lexus.

[0038] 3. The formula of TB medium is: 11.8 g tryptone, 23.6 g yeast extract, 9.4 g K2HPO4, 2.2 gKH2PO4, 4 ml glycerol, 996 ml water.

[0039] 4. 1640 culture medium is SepNuo RPMI-1640 culture medium.

[0040] 5. DMEM culture medium is SepNuo DMEM culture medium.

[0041] Example 1 Sequence of recombinant human fibronectin The present embodiment provides a recombinant human fibronectin, whose amino acid sequence is shown in SEQ ID NO.1, and the corresponding nucleotide sequence of the encoding gene is shown in SEQ ID NO.2. The nucleotide sequence shown in SEQ ID NO.2 is optimized by genetic engineering codons to be optimized to a nucleotide sequence shown in SEQ ID NO.3, so that the amino acid sequence shown in SEQ NO.1 can be better expressed in the host bacteria. Different tag sequences are added to both sides of the nucleotide sequence shown in SEQ ID NO.3. The improvement of amino acid expression by adding different tag sequences is shown in Table 1. The different tagged proteins are predicted and analyzed by Rosetta, and the preferred sequence is TrxA (containing HIS tag sequence, as shown in SEQ ID NO.4) after comprehensive comparison.

[0042] Table 1

[0043] Figure 1 This is the structure prediction of proteins under different tags. The prediction results come from the rosetta website. The left picture shows the experimental results without tags, and the right picture shows the results with tags added. From the results, the protein with tags added has a more compact protein structure, which promotes the stability of the protein. The TrxA tag cannot predict the protein results, so there is no specific protein structure diagram. It is speculated that using this tag will have very clear results compared with traditional protein expression. The GST domain promotes the linearity of protein results, making the protein structure more independent and three-dimensional, increasing the possibility of expression. The results of protein structure prediction are also consistent with the prediction results in Table 1.

[0044] Example 2 Construction and screening of recombinant human fibronectin strains The specific process is as follows: (1) Plasmid synthesis: The gene encoding human fibronectin (as shown in SEQ ID NO.4) was subcloned into the NcoⅠ and KpnⅠ restriction sites of pET32a(+) to obtain the recombinant plasmid pET32a-FN. Figure 2 The recombinant plasmid shown has a full set of operating elements for gene expression, and can express the target heterologous protein through the Lac operon. The protein after codon optimization has good compatibility with the host and can be expressed efficiently in the host cell. The electrophoresis diagram of the recombinant plasmid pET32a-FN is shown in Figure 3 shown.

[0045] (2) Host cell transformation: transform the recombinant plasmid pET32a-FN and the successfully constructed expression plasmid into E. coli competent cells BL21 (DE3). The specific process is as follows: Take out the EP tube containing E. coli competent cells BL21 (DE3) from the ultra-low temperature refrigerator and place it on ice. When it is half-melted, take 2μl of the plasmid to be transformed and add it to the E. coli competent cells BL21 (DE3), and manually invert the EP tube to mix 2-6 times. Place the mixture of recombinant plasmid pET32a-FN and BL21 (DE3) competent cells on ice for 25-35min, then place it in a 42°C water bath for heat shock for 60-90s, and immediately place it on ice for 1.5-2.5min after taking it out. Transfer the above-mentioned transformed BL21 (DE3) bacterial solution to the clean bench, add 700μl liquid SOB culture medium, and then culture it in a constant temperature shaking incubator at 37°C and 220 rpm for 40-120 min. Take 100-200 μl of bacterial solution and evenly spread it on SOB plates containing 50μg / ml ampicillin sodium, a total of 5 plates. The coated plate was inverted and placed in a constant temperature incubator at 37°C for 16-24 hours until monoclonal colonies clearly visible to the naked eye grew out.

[0046] (3) Strain screening: 5-10 monoclonal strains were picked from the above plates and inoculated into TB medium shake flasks containing 100 μg / ml ampicillin sodium. The shake flasks were cultured at 220 rpm and 37°C for 4-6 h. The shake flasks were then cooled to 25-28°C. IPTG with a final concentration of 0.5 mM was added to induce expression for 6-8 h. The bacterial solution was divided into centrifuge bottles and centrifuged at 8500 rpm and 4°C for 10-15 min. The bacterial cells were collected and their weights were recorded. Samples were taken (2 ml of bacterial solution was taken every hour before and after induction and centrifuged at 8000 rpm for 2 min to obtain bacterial cells) for electrophoresis detection. The collected bacterial cells were resuspended in PB buffer (20 mMPB, pH 7.4) and disrupted by ultrasound. After completion, the disrupted bacterial solution was collected and centrifuged at 8000 rpm and 8°C for 45 min. The supernatant and precipitate were taken for electrophoresis detection. The electrophoresis results were scanned and analyzed, and a monoclonal strain with a higher expression of recombinant human fibronectin was selected for strain preservation to obtain a genetically engineered bacterium expressing human recombinant fibronectin.

[0047] Example 3 Fermentation and optimization of recombinant human fibronectin strain The fermentation and optimization of the strains were performed in a shake flask: 600 μl of ampicillin and 6000 μl of glycerol seed solution (the genetically engineered bacteria obtained in Example 2) were respectively taken into 600 ml of sterile TB medium using a pipette, the bottle mouth was bandaged, and the configuration was placed in a shaker as a basic configuration; before induction, the culture was cultured at 37°C to a specific OD 600 value.

[0048] The fermentation conditions were optimized as shown in Table 2, and the best expression conditions were screened by single factor analysis.

[0049] Table 2

[0050] After optimization, the optimal expression conditions are as follows: 37°C, 150rpm, culture for 6-8 h, OD 600 After reaching 2-3, IPTG was added to make the final concentration reach 0.5 mM / l, and the induction was continued at 37 degrees for 5 hours; the induction was completed. The expression level of fibronectin after optimization was detected, and the results were as follows Figure 4 As shown, from Figure 4 Comparison of lane 1 with other lanes shows that IPTG induces the expression of fibronectin, and the expression level gradually increases over time. Optimized expression results in a relatively high yield, with the wet cell count reaching 95 g / l.

[0051] Example 4 Purification of recombinant human fibronectin protein The induced bacterial liquid obtained in Example 3 was balanced and placed in a centrifuge, centrifuged at 6500 rpm for 35 min, and the selected temperature was 8°C, and the bacterial precipitate was collected; the bacteria were resuspended in 50 mM PB (pH 8.0), and ultrasonically disrupted for 45 min, 3 s, 2 s interval, and a power of 455 watts to release the recombinant protein from the bacteria. The disrupted bacteria were separated by centrifugation to separate the protein supernatant and the precipitate, and the centrifugation conditions were 6500 rpm, 35 min, and the selected temperature was 8°C.

[0052] Because the 6*HIS histidine part on the TrxA tag on the vector can bind strongly to the nickel column under appropriate conditions, affinity chromatography is used to separate impurities. Before chromatography, the supernatant needs to be filtered with a 0.45 μm or 0.22 μm filter membrane. The balance solution used for chromatography is 20 mM imidazole, 50 mM PB (pH 8.0), and the elution buffer is 500 mM imidazole, 50 mM PB (pH 8.0). Linear elution is performed, and the peak with appropriate molecular weight is selected by SDS-PAGE detection for subsequent purification. After the elution peak is desalted, 0.01-1% EK enzyme is added to the system, and the reaction condition is 4 ℃ overnight. The protein solution after enzyme cleavage is again subjected to the above affinity chromatography to collect the flow-through peak. The flow-through peak is concentrated by ultrafiltration and stored in 50 mM PBS (pH 8.0).

[0053] Using commercially available fibronectin as a control, the purity was tested by HPLC. The results are as follows Figure 5 As can be seen from the figure, the fibronectin purified by the purification method of the present invention has a higher purity than commercially available fibronectin.

[0054] The solubility and stability of the recombinant fibronectin obtained in this example were tested. Natural fibronectin is a water-insoluble protein. The concentration of commercially available recombinant human fibronectin is mostly at the level of 1000 ppm. The recombinant human fibronectin prepared in the present invention currently has a concentration greater than 8 mg / ml.

[0055] The fibronectin of this example has strong stability. The fibronectin of the fibronectin shown can maintain temperature stability for at least 6 hours in an 80 degree water bath environment. For detailed results, see Figure 6 In addition, the fibronectin of the present invention is freeze-thaw stable. With the addition of an appropriate amount of salt, it exhibits the opposite property of the traditional fibronectin being cold insoluble. It also maintains the stability of the aqueous solution at low temperatures. In the case of repeated freezing and thawing, no bands with obvious molecular weight reduction appear within three times. The recombinant human fibronectin is freeze-thaw stable. For details, see Figure 7 .

[0056] Example 5 Cellular Activity Detection of Recombinant Human Fibronectin Protein NIH 3T3 cell proliferation assay: Control group: commercially available product (sale-Fn), Aladdin full-length recombinant fibronectin (rfull-Fn), catalog number: rp155944-200μg Test sample: Recombinant protein (rFn) obtained in Example 4 The four groups of samples were sample 1 (rFn), control 1 (sale-Fn), and control 2 (rfull-Fn); Control 1 was used as a negative control, and control 2 was used as a positive control. After weighing an appropriate amount of each group of samples, they were dissolved in sterile PBS, filtered through a 0.22 μM filter, and gradiently diluted to 100 μg / ml, 20 μg / ml, 4 μg / ml, 0.8 μg / ml, 0.16 μg / ml, 0.032 μg / ml, and 0.0064 μg / ml. After mixing, they were added to a 96-well plate at 100 μl / well, coated at 37°C for 1 hour, and three replicates were used for each group.

[0057] Pour out the liquid in the coated 96-well plate, add 200 μl sterile PBS to each well, wash twice, and set aside. Take NIH 3T3 cells in the logarithmic growth phase, count the cells, and adjust the cell concentration to 6×10 3 / well was inoculated into the treated 96-well plate of each group, and cultured in a 5% CO2, 37℃ constant temperature incubator for 60h. RMPI 1640 medium was removed. Each well was washed three times with PBS, and a medium containing 10% CCK-8 was added at 100μL / well, and cultured in a 5% CO2, 37℃ constant temperature incubator for 2 hours. The absorbance value at 450 nm was detected by an enzyme marker.

[0058] The results of cell viability were as follows Figure 8 As shown in the figure, it can be seen that the cell proliferation activity results under the method of the present invention are compared with fibronectin from different sources. The results show that the fibronectin shown in the present invention has similar activity results as the recombinant full-length fibronectin (rice expression), the commercialized fibronectin has no cell proliferation activity, and the control recombinant human fibronectin obtained from other places also has no cell proliferation activity.

[0059] HaCaT cell proliferation activity detection; The samples were diluted to the appropriate concentrations, i.e., 0.0008 μg / ml, 0.0016 μg / ml, 0.0032 μg / ml, 0.0064 μg / ml, 0.0125 μg / ml, 0.025 μg / ml, 0.05 μg / ml, and 0.1 μg / ml. The diluent used was serum-free medium DMEM. The cells were seeded in 24-well plates and incubated overnight in an incubator (37°C, 5% CO2, 95% RH). The experiment was divided into 10 groups, the blank control was serum-free medium, the positive control was DMSO serum-free medium group containing toxic substances, and the experimental group was serum medium at the above concentration. When the cell plating rate in the 24-well plate reached about 80%, the drugs were grouped and administered, with 3 replicates in each group. The cells were incubated in an incubator (37°C, 5% CO2, 95% RH) for 24 h. The cells were washed three times with PBS, 200 μl of 0.5 mg / ml MTT was added, and the cells were incubated at 37°C for 4 h. The supernatant was discarded, and 200 μl of DMSO was added to measure the absorbance at 570 nm.

[0060] like Fig. 9 As shown, the proliferation activity of HaCaT cells under the method of the present invention gradually increases with the increase of the concentration of the sample used.

[0061] Comparative Example 1 According to the method of Example 2, a genetically engineered bacterium containing a gene fragment with a nucleotide sequence such as SEQ ID NO. 2-3 was constructed, and protein expression was performed according to the optimal fermentation expression conditions of Example 3, and protein expression was detected by SDS-PAGE. Fig.10 As can be seen from the figure, the sequence without codon optimization has no expression or very low expression in the host, the expression level of untagged protein in the body is low, and the yield of the fermentation result after optimization of the tagged strain is higher than that of the conventional fermentation result with the tag.

[0062] Comparative Example 2 The crude product obtained under the optimal fermentation expression conditions in Example 3 was purified using a conventional purification method, as follows: The traditional purification method is to purify by saturated ammonium sulfate gradient, and obtain by molecular sieve or anion and cation exchange. Specifically, the saturated ammonium sulfate concentration is 33%, and the anion and cation exchange is strong anion exchange. The above-obtained pure fibronectin, the pure fibronectin obtained in Example 4, and other commercially available fibronectin were detected by SDS-PAGE.

[0063] like Fig.11 As shown, the commercially available fibronectin has a higher purity after the purification method of the present invention than that obtained by other traditional purification methods.

[0064] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A recombinant human fibronectin, characterized in that: The amino acid sequence is shown in SEQ ID NO.

1.

2. A gene encoding the protein according to claim 1.

3. A recombinant plasmid carrying the gene according to claim 2.

4. A genetically engineered bacterium, wherein the genetically engineered bacterium is a host cell expressing the fibronectin according to claim 1, or containing the gene according to claim 2, or transformed with the plasmid according to claim 3.

5. The genetically engineered bacterium according to claim 4, characterized in that: The host cell comprises a prokaryotic or eukaryotic microorganism.

6. A method for preparing recombinant human fibronectin, the method comprising culturing the genetically engineered bacteria according to claim 4, inducing the bacteria to express recombinant fibronectin, disrupting the bacteria, and obtaining a crude recombinant fibronectin product.

7. The method according to claim 6, characterized in that The genetically engineered bacteria were inoculated in a liquid culture medium, cultured at 37°C and 220 rpm for 4-6 hours, 0.1-1 M IPTG was added, induced at 25-37°C and 220 rpm for 6-8 hours, centrifuged to remove the supernatant, ultrasonically disrupted the bacteria, and centrifuged to collect the supernatant to obtain a crude product.

8. The method according to claim 6, characterized in that The crude recombinant fibronectin product is purified to obtain a pure recombinant fibronectin product.

9. Use of the protein according to claim 1, or the gene according to claim 2, or the plasmid according to claim 3, or the genetically engineered bacteria according to claim 4 or 5, or the method according to any one of claims 6 to 8 in the preparation of a product containing fibronectin.

10. A method for detecting fibronectin activity, characterized in that: The method comprises culturing mouse fibroblasts NIH 3T3 with 1640 medium added with a fibronectin sample to be detected, replacing it with 1640 medium containing 10% CCK8 after 60 hours and culturing it for 2 hours, and detecting the absorbance at 450 nm; Alternatively, the method is to culture human keratinocytes HaCaT in a DMEM medium supplemented with a fibronectin sample to be detected, replace it with a DMEM medium containing 0.5 mg / mL MTT after 24 hours, culture it for 4 hours, discard the supernatant DMSO, and detect the absorbance at 570 nm.

Citation Information

Patent Citations

  • Fibronectin fragment to be used for stem cell production

    CN109790536A

  • Saccharomyces cerevisiae expressed long-acting recombinant fibronectin and application thereof in cosmetics

    CN113186109A

  • Recombinant human fibronectin as well as preparation method and application thereof

    CN115975004A

  • Recombinant human fibronectin mutant with enhanced protein stability and expression strain thereof

    CN116574173A

  • Recombinant fibronectin Pro. FN as well as preparation method and application thereof

    CN117186246A

Cited By

  • Recombinant human fibronectin composition as well as preparation method and application thereof

    CN120478254A

  • A recombinant human-derived fibronectin composition, and a method of preparing and using the same

    CN120478254B